Autres langues Voyager Therapeutics, Inc.

Actions

VYGR

US92915B1061

Temps réel estimé Cboe BZX Autres places de cotation 20:45:12 26/04/2024			Varia. 5j.	Varia. 1 janv.
7,605 ^USD	+2,49 %		+1,60 %	-9,72 %

02/04	Voyager Therapeutics, Inc. nomme Robin Swartz au poste de comptable principal	CI
26/03	VOYAGER THERAPEUTICS, INC. : Guggenheim toujours à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	22/04
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	16/04
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	16/04
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer	02/04
Voyager Therapeutics, Inc. Announces CFO Changes	02/04
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	27/03
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	26/03
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) added to S&P Biotechnology Select Industry Index	18/03
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer	13/03
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer	13/03
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024	13/03
Voyager Therapeutics: Q4 Earnings Snapshot	28/02
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	28/02
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	27/02
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast	21/02
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research	20/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Voyager Therapeutics, Inc.

Actions

VYGR

US92915B1061

Autres langues

Filtres